Paraneoplastic syndromes secondary to neuroendocrine tumours.
Neuroendocrine tumours may be either benign or malignant tumours, and have the ability to synthesise and secrete biologically active substances characteristic of the cell of origin that can cause distinct clinical syndromes. The term 'paraneoplastic syndromes' (PNSs) is used to denote synd...
Main Authors: | Kaltsas, G, Androulakis, I, de Herder, W, Grossman, AB |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2010
|
Similar Items
-
Gastroenteropancreatic neuroendocrine tumours.
by: Modlin, I, et al.
Published: (2008) -
The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.
by: Kaltsas, G, et al.
Published: (2001) -
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
by: Kaltsas, G, et al.
Published: (2005) -
The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours.
by: Kaltsas, G, et al.
Published: (2001) -
Update on neuroendocrine tumours
by: Grossman, AB
Published: (2012)